T-ALL

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference

Retrieved on: 
수요일, 11월 10, 2021
Cancer, T-Cell Acute Lymphoblastic Leukemia, T-ALL, TNBC, Novartis, NASDAQ, Plantar fibromatosis, ACC, MM, GMT, Patient, Neoplasm, Conference, Ayala, GLOBE, Event, Therapy, Multiple myeloma, Webcast, Adenoid cystic carcinoma, AYLA, FDA, Pharmaceutical industry

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).
  • A live webcast of the fireside chat may be accessed by visiting the Events & Presentations section of Ayalas website at ir.ayalapharma.com .
  • An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

Wugen to Present Virtually at the Upcoming Jefferies London Healthcare Conference

Retrieved on: 
수요일, 11월 10, 2021
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Other Health, T-cell acute lymphoblastic leukemia, Infection, AML, Acute leukemia, T-ALL, Conference, NK, Vaccine

Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in the upcoming Virtual Jefferies London Healthcare Conference set to take place November 16 - 19, 2021.

Key Points: 
  • Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in the upcoming Virtual Jefferies London Healthcare Conference set to take place November 16 - 19, 2021.
  • The presentation will be available to registered conference attendees for on-demand viewing on Thursday, November 18 at 8:00 a.m. GMT (3:00 a.m.
  • Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies.
  • Wugen is also advancing WU-CART-007, currently in development for T-cell acute lymphoblastic leukemia (T-ALL).

Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Retrieved on: 
화요일, 11월 9, 2021
Professional Services, Health, Other Science, Finance, General Health, Research, Science, T-cell acute lymphoblastic leukemia, Infection, SITC, AML, Immunotherapy, Memory, Acute leukemia, LBL, Abstract (summary), T-ALL, Society, NK, Phenotype, Pharmaceutical industry, Vaccine

The data highlight Wugens proprietary large-scale feeder-cell free manufacturing process and demonstrate WU-NK-101s robust memory phenotype and enhanced anti-tumor activity.

Key Points: 
  • The data highlight Wugens proprietary large-scale feeder-cell free manufacturing process and demonstrate WU-NK-101s robust memory phenotype and enhanced anti-tumor activity.
  • Further, the data demonstrate that in combination with monoclonal antibodies, WU-NK-101 exhibits enhanced efficacy against solid tumor cell lines.
  • The details of Wugens presentation at SITC are as follows:
    Abstracts will be available Tuesday, November 9, 2021, at 8:00 a.m.
  • Wugen is also advancing WU-CART-007, an allogeneic CAR-T currently in development for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL).

Wugen Announces Data Presentation at the 63rd Annual Society of Hematology (ASH) Annual Meeting

Retrieved on: 
목요일, 11월 4, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, T-cell acute lymphoblastic leukemia, Society, Infection, AML, T-ALL, Acute leukemia, LBL, ASH, NK, NCT, Vaccine

The results demonstrate preclinical safety and anti-tumor activity of WU-CART-007.

Key Points: 
  • The results demonstrate preclinical safety and anti-tumor activity of WU-CART-007.
  • Wugen is preparing to begin enrollment for a Phase 1/2 clinical trial for relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL) (NCT#04984356).
  • Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection.
  • Wugen is also advancing WU-CART-007, currently in development for T-cell acute lymphoblastic leukemia (T-ALL).

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting

Retrieved on: 
목요일, 11월 4, 2021
Exposition, CD19, Non-Hodgkin lymphoma, NHL, Technology, LinkedIn, Cancer, Industry, Annual report, Form 20-F, PALO, CAR, Security (finance), U.S. Securities and Exchange Commission, Patient, Allotransplantation, NASDAQ, Lymphocyte, Private Securities Litigation Reform Act, HVG, ALL, Graft-versus-host disease, T-ALL, ASH, Lymphatic system, B-ALL, Acute lymphoblastic leukemia, Senior, Risk, CD7, Research and development, EST, Holm–Bonferroni method, Lymphoid leukemia, Bone marrow, Therapy, Gene editing, Society, Pharmaceutical industry, Vaccine, Medical imaging

GC502 is a CD19/CD7 dual-directed, stand-alone off-the-shelf allogeneic CAR-T therapy for the treatment of B-cell malignancies developed on Gracell's proprietary TruUCAR technology platform.

Key Points: 
  • GC502 is a CD19/CD7 dual-directed, stand-alone off-the-shelf allogeneic CAR-T therapy for the treatment of B-cell malignancies developed on Gracell's proprietary TruUCAR technology platform.
  • "GC502 displays strong anti-tumor potency and suppression of HvG response in the preclinical study.
  • Gracell Biotechnologies Inc.("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.
  • Readers should not rely upon the information on this page as current or accurate after its publication date.

Burlington Stores and The Leukemia & Lymphoma Society Celebrate 20 Years of Partnership in the Fight Against Blood Cancer

Retrieved on: 
월요일, 10월 18, 2021
Instagram, Patient, Degenerative disease, Leukemia, New, Lymphatic system, Survivor, Cancer, Initiative, Doctor of Philosophy, T-ALL, Beauty, Policy, Abdominal pain, LLS, Nausea, Human, Disease, Lymphoma, Clinical trial, RYE, Fatigue, Government budget balance, Multiple myeloma, Company, Quality of life, CEO, Fiscal, Leukemia & Lymphoma Society, Vomiting, Twitter, Research, Partnership, T-cell acute lymphoblastic leukemia, Birth control, Pharmaceutical industry

A donation made at checkout can provide support towards cutting-edge blood cancer research and help improve the lives of children like five-year-old Leo.

Key Points: 
  • A donation made at checkout can provide support towards cutting-edge blood cancer research and help improve the lives of children like five-year-old Leo.
  • The treatment protocol for his type of leukemia is a three-and-a-half-year process that includes several phases of chemotherapy.
  • "We couldn't be more thrilled to celebrate 20 tremendous years of partnership and continued commitment to support LLS's mission and the LLS Children's Initiative," said Michael O'Sullivan, CEO, Burlington Stores.
  • The Leukemia & Lymphoma Society (LLS) is the global leader in the fight against blood cancer.

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Retrieved on: 
목요일, 9월 23, 2021
People, T-Cell Acute Lymphoblastic Leukemia, Recurrence, ACC, Private Securities Litigation Reform Act, Quality, Growth, Safety, Aggressive fibromatosis, Adenoid cystic carcinoma, SEC, Confidentiality, T-ALL, PR, U.S. Securities and Exchange Commission, TNBC, Abdominal wall, Adult, Incidence, BMS, Organ dysfunction, PFS, Clinical trial, Current Oncology, Neoplasm, Annual report, Therapy, AYLA, NASDAQ, Plantar fibromatosis, FDA, Cancer, Multiple myeloma, ORR, MM, QOL, GLOBE, Chronic pain, MRI, Novartis, Risk, Doctor of Philosophy, Patient, Adolescence, Ownership, Head, Pivotal, COVID-19, DOR, Research, Quality of life, Pharmaceutical industry, Medical imaging

This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.

Key Points: 
  • This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.
  • The data included in the case study are based on earlier Phase 1 results and compassionate use of AL101 in desmoid tumors.
  • Both of these patients case studies represent additional evidence to support the development of our gamma secretase inhibitor, AL102 for the treatment of desmoid tumors.
  • The body of data conducted by BMS in patients with desmoid tumors implicating the role of gamma secretase inhibition furthers our hypothesis for treating desmoid tumors through AL102s mechanism of action, said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala.

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

Retrieved on: 
목요일, 9월 16, 2021
Patient, Adenoid cystic carcinoma, T-Cell Acute Lymphoblastic Leukemia, FGFR, Hepatotoxicity, Malignancy, Plantar fibromatosis, Doctor of Philosophy, Neoplasm, Trae tha Truth, Exocrine gland, Research, Phase II, U.S. Securities and Exchange Commission, Oncology, Risk, HDAC, Confidentiality, Ownership, Lead, Pivotal, Private Securities Litigation Reform Act, RECIST, Gene expression, Annual report, Therapy, NASDAQ, Growth, COVID-19, GLOBE, Fast track (FDA), Notch 1, Cancer, PDX, Incidence, T-ALL, FDA, AES, AYLA, MM, HIV disease progression rates, Bristol Myers Squibb, Safety, ACC, Death, Recurrence, SEC, Seizure, Novartis, TNBC, GSI, Metastasis, Clinical trial, Disease, Multiple myeloma, Diarrhea, Pharmaceutical industry, Medical imaging, Health insurance

REHOVOT, Israel and WILMINGTON, Del., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations. The data is being presented at the 2021 ESMO Virtual Congress as an ePoster. In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.

Key Points: 
  • In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.
  • R/M ACC remains a significant area of unmet need, and I am encouraged by the preliminary results that AL101 monotherapy has demonstrated to-date.
  • The preliminary safety and efficacy data from the 6mg cohort of our ongoing ACCURACY trial of AL101 highlights a favourable profile.
  • Preliminary Safety and Efficacy Data from 6mg Cohort of ACCURACY Phase 2 Trial:
    Ayala presented new preliminary 6mg data from its ongoing ACCURACY Phase 2 clinical trial evaluating the safety and efficacy of AL101 monotherapy for the treatment of patients with R/M ACC harboring Notch-activating mutations.

Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Retrieved on: 
목요일, 9월 2, 2021
Webcast, ACC, Therapy, Cancer, GLOBE, T-ALL, TNBC, T-Cell Acute Lymphoblastic Leukemia, Event, Pivotal, NASDAQ, Patient, AYLA, MM, Plantar fibromatosis, Novartis, Conference, Neoplasm, FDA, Ayala, Adenoid cystic carcinoma, Multiple myeloma, Pharmaceutical industry

REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September:

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in two upcoming virtual investor conferences in September:
    H.C. Wainwright 23rd Annual Global Investor Conference: Corporate Presentation available on-demand starting Monday, September 13, 2021 at 7:00 am ET.
  • Citis 16th Annual Biopharma Virtual Conference: Management will participate in investor meetings on Thursday, September 9, 2021.
  • A webcast of the H.C. Wainwright 23rd Annual Global Investor Conference presentation may be accessed by visiting the Events & Presentations section of Ayalas website at ir.ayalapharma.com .
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

Retrieved on: 
수요일, 9월 1, 2021
European Society for Medical Oncology, Fast track (FDA), GSI, ACC, Therapy, Cancer, GLOBE, T-ALL, TNBC, T-Cell Acute Lymphoblastic Leukemia, Phase II, ESMO, Clinical trial, Pivotal, NASDAQ, Notch 1, Patient, Oncology, AYLA, MM, Plantar fibromatosis, Novartis, Neoplasm, Bristol Myers Squibb, Adenoid cystic carcinoma, FDA, Ayala, Multiple myeloma, Pharmaceutical industry

Ayala will present preliminary data from the 6mg cohort of the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harbouring Notch-activating mutations in addition to preclinical results from Ayalas new study of AL101 in combination with other drugs for dual targeting of Notch dysregulated tumors.

Key Points: 
  • Ayala will present preliminary data from the 6mg cohort of the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harbouring Notch-activating mutations in addition to preclinical results from Ayalas new study of AL101 in combination with other drugs for dual targeting of Notch dysregulated tumors.
  • AL101 is designed to inhibit the expression of Notch gene targets by blocking the final cleavage step by the gamma secretase required for Notch activation.
  • Ayala obtained an exclusive, worldwide license to develop and commercialize AL101 from Bristol-Myers Squibb Company in November 2017.
  • AL101 was granted U.S. FDA Fast Track Designation and Orphan Drug Designation for the treatment of ACC.